A recent trial successfully achieved its primary safety benchmarks and important secondary efficacy goals, leading to the decision to move forward with Phase 3 development later in the second half of 2026. The trial results were promising for Cyrano Therapeutics, Inc., a regenerative medicine company based in DELRAY BEACH, Fla. This milestone marks a significant step towards further progress in their innovative work.